GRAIL Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Joshua J. Ofman
- Full Time Employees
- 910
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 1525 O’Brien Drive Menlo Park CA United States of America 94025
- IPO Date
- Jun 12, 2024
- CIK
- 0001699031
- Website
- grail.com
- Similar Companies
- Business
- GRAIL, Inc. is a biotechnology company headquartered in Menlo Park, California, founded in 2015, specializing in early cancer detection through advanced biotechnology and genomics. The company develops and commercializes the Galleri test, a multi-cancer early detection (MCED) blood test designed to screen for multiple types of cancer at early, asymptomatic stages using targeted methylation-based next-generation sequencing technologies combined with machine learning and automation. GRAIL's core offerings include multi-cancer early detection assays, tests for risk stratification, minimal residual disease detection, biomarker subtyping, and tools for treatment and recurrence monitoring. Its technologies aim to support the continuum of care in oncology from screening to precision medicine. GRAIL operates primarily in the United States, with additional locations in Washington, D.C., North Carolina, and the United Kingdom, serving a global healthcare market including symptomatic and asymptomatic patients. In recent years, GRAIL completed its spin-off from Illumina in June 2024 following regulatory mandates by European authorities, thereby transitioning into an independent publicly traded company (Ticker: GRAL). The separation marked a major strategic shift as Illumina had previously acquired GRAIL in 2021 but was required to divest due to antitrust concerns. Since becoming independent, GRAIL has expanded commercial sales of its Galleri test, reporting a 39% year-over-year increase in test volume and reaching $32.6 million in revenue in the third quarter of 2025. The company also announced ongoing pivotal registrational studies with plans to read out results in 2025 and 2026 supporting FDA submission and adoption. Strategic partnerships, such as a collaboration with athenahealth, aim to streamline ordering and integrate Galleri testing into broader healthcare provider workflows. GRAIL continues to focus on operational efficiencies, business growth, and market penetration in multi-cancer early detection, reinforced by recent data demonstrating improved test accuracy and expanding clinical validation efforts. GRAIL's business is positioned at the intersection of biotechnology, oncology diagnostics, and precision medicine within the broader healthcare industry. Its primary customer base includes healthcare providers, oncologists, and health systems engaged in cancer screening and early detection. Key products include the Galleri multi-cancer early detection blood test, supported by proprietary sequencing and analytic platforms that harness population-scale clinical data and AI-driven interpretation. The company targets markets in the United States and internationally, with a strong emphasis on regulatory clearance, clinical utility demonstration, and adoption within preventive health and oncology care pathways. GRAIL maintains a commitment to innovation in early cancer detection technology while addressing challenges in the evolving landscape of liquid biopsy diagnostics. Overall, GRAIL represents a leading innovator in early-stage cancer screening and precision oncology diagnostics, building on foundational genomic sequencing technologies and strategic pivots to independence and commercial expansion in the competitive biotech sector focused on cancer mortality reduction. Recent developments underline the company's transition to a growth-oriented, standalone entity with increasing commercial traction and regulatory milestones anticipated in the near term.
Company News
Grail Stock Jumps in August as FDA Schedules a Key Meeting for its Galleri Cancer Test
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GRAIL to Present at Morgan Stanley's 24th Annual Global Healthcare Conference
GRAIL Highlights Galleri Growth Ahead of Key FDA Advisory Meeting
Bank of America Corp DE Purchases 205,611 Shares of GRAIL, Inc. $GRAL
GRAIL: Looking Beyond The NHS-Galleri Headline
FDA Panel Schedules to Evaluate GRAIL Premarket Approval Application for Multi-Cancer Early Detection Test
GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test
US FDA to hold advisory meeting to review Grail's multi-cancer test
GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test
GRAIL, Inc. (GRAL) Q2 2026 Earnings Call Transcript
GRAIL Q2 Earnings Call Highlights
GRAIL Reports Second Quarter 2026 Financial Results
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GRAIL, Inc. of Class Action Lawsuit and Upcoming Deadlines – GRAL
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026
Bronstein, Gewirtz & Grossman LLC Urges GRAIL, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
GRAL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in GRAIL, Inc. Securities Lawsuit - Contact The Gross Law Firm
Portnoy Law Firm Announces Class Action on Behalf of Grail, Inc. Investors
GRAL DEADLINE TODAY: GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
GRAL DEADLINE TODAY: GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit